Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 32Rectal Neoplasms 25Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Head and Neck Neoplasms 20Central Nervous System Neoplasms 19Lung Neoplasms 18Prostatic Neoplasms 17Lymphoma 17Esophageal Squamous Cell Carcinoma 17Leukemia 16Glioblastoma 16Squamous Cell Carcinoma of Head and Neck 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Hepatocellular 12Sarcoma 10Neuroblastoma 10Neoplasms 10Nasopharyngeal Carcinoma 10Brain Neoplasms 10Astrocytoma 10Colorectal Neoplasms 9Pancreatic Neoplasms 7Glioma 7Neoplasm Metastasis 6Nasopharyngeal Neoplasms 6Lymphoma, Non-Hodgkin 6Stomach Neoplasms 5Recurrence 5

Interventions

Verteporfin 1Radiotherapy 1Gelclair 1Etoposide 1Erlotinib Hydrochloride 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Familial ependymoma × Radiotherapy × Clear all
NCT00360854 2013-09-20

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

National Cancer Institute (NCI)

Phase 1 Unknown
48 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡